Krystal Biotech, Inc. (KRYS) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was $205M, a net margin of 52.6%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $470M and net income $225M.
Free cash flow was $189M in fiscal 2025 and positive in 2 of the 10 years shown.
The diluted share count rose 3313% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $470M | $389M | $291M | $51M | $0 | $0 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | $228M | $161M | $66M | -$110M | -$145M | -$68M | -$33M | -$22M | -$12M | -$5M | -$1M |
| Net income | $225M | $205M | $89M | $11M | -$140M | -$70M | -$32M | -$19M | -$11M | -$8M | -$1M |
| EPS (diluted) | $7.37 | $6.84 | $3.00 | $0.39 | $-5.49 | $-3.13 | $-1.71 | $-1.20 | $-0.97 | $-1.48 | $-1.31 |
| R&D | $60M | $58M | $54M | $46M | $42M | $28M | $18M | $16M | $8M | $3M | $741000 |
| Revenue growth | — | +33.9% | +473.0% | — | — | — | — | — | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $324M | $201M | $123M | -$89M | -$101M | -$48M | -$26M | -$19M | -$9M | -$4M | -$1M |
| Capital spending | -$14M | -$12M | -$4M | -$12M | -$53M | -$68M | -$15M | -$6M | -$2M | -$210000 | -$15000 |
| Free cash flow | $310M | $189M | $119M | -$101M | -$154M | -$116M | -$41M | -$25M | -$12M | -$4M | -$1M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $55M | $55M | $49M | $40M | $33M | $15M | $3M | $1M | $792000 | $246000 | $33000 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $828M | $598M | $532M | $379M | $438M | $271M | $194M | $112M | $50M | $2M |
| Debt | — | $9M | $7M | $8M | $9M | $8M | $4M | $3M | — | $0 | $2M |
| Equity | — | $1.2B | $946M | $779M | $522M | $594M | $292M | $203M | $113M | $49M | $289000 |
| Total assets | — | $1.3B | $1.1B | $818M | $558M | $626M | $311M | $209M | $116M | $50M | $2M |
| Shares (diluted) | 31M | 30M | 30M | 28M | 25M | 22M | 19M | 16M | 11M | 5M | 1M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | 48.4% | 41.4% | 22.6% | -216.2% | — | — | — | — | — | — | — |
| Net margin | 47.9% | 52.6% | 30.7% | 21.6% | — | — | — | — | — | — | — |
| FCF margin | 66.0% | 48.5% | 41.0% | -198.4% | — | — | — | — | — | — | — |
| ROIC | — | 10.4% | 6.5% | -11.8% | -27.3% | -11.3% | -8.8% | -8.5% | -8.3% | -7.6% | -43.2% |
| ROE | — | 16.8% | 9.4% | 1.4% | -26.8% | -11.7% | -11.0% | -9.4% | -9.6% | -16.0% | -397.9% |
Frequently asked questions
What is Krystal Biotech’s annual revenue?
$389M in fiscal 2025 and $470M over the twelve months to September 30, 2026.
How much profit does Krystal Biotech make?
Net income was $205M in fiscal 2025 (net margin 52.6%).
Is Krystal Biotech’s revenue growing?
Yes: revenue rose 33.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.